Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Establishment Labs breaks ground on third facility in Costa Rica » 13:05
06/23/21
06/23
13:05
06/23/21
13:05
ESTA

Establishment Labs

$81.06 /

+2.1 (+2.66%)

Establishment Labs held…

Establishment Labs held the groundbreaking ceremony for its new SulayIom Innovation Campus in Costa Rica. When complete, the new facilities will total approximately 145,000 square feet and will support the company's continued global growth with additional capacity and capabilities in manufacturing, R&D, digital media, training, and medical education. The new campus will be completed in two phases with the first phase expected to cost approximately $35M, the majority of which the company intends to finance with a local credit partner. Construction on the new building will begin following finalization and execution of certain contractual arrangements. The new facilities will add up to 1,000 new jobs over the next several years and will be located in the Coyol Free Zone in Costa Rica.

ShowHide Related Items >><<
ESTA Establishment Labs
$81.06 /

+2.1 (+2.66%)

ESTA Establishment Labs
$81.06 /

+2.1 (+2.66%)

06/23/21 BTIG
Establishment Labs price target raised to $88 from $82 at BTIG
02/10/21 Cowen
Establishment Labs price target raised to $80 from $60 at Cowen
01/13/21 BTIG
Establishment Labs price target raised to $61 from $41 at BTIG
01/12/21 Jefferies
Allergan exits a 'clear win' for Establishment Labs, says Jefferies
ESTA Establishment Labs
$81.06 /

+2.1 (+2.66%)

Recommendations
Establishment Labs price target raised to $88 from $82 at BTIG » 09:33
06/23/21
06/23
09:33
06/23/21
09:33
ESTA

Establishment Labs

$78.96 /

-1.4 (-1.74%)

BTIG analyst Marie…

BTIG analyst Marie Thibault raised the firm's price target on Establishment Labs to $88 from $82 and keeps a Buy rating on the shares. The analyst is citing the company's disclosed publishing of "positive finding" in the study evaluating its SmoothSilk implants' biocompatibility, which found that breast implants "kick off a foreign body response that varies by surface texture". Thibault adds that the study revealed that while the inflammatory response was strongest with macrotextured breast implants, Establishment Labs' SmoothSilk surface was least inflammatory.

ShowHide Related Items >><<
ESTA Establishment Labs
$78.96 /

-1.4 (-1.74%)

ESTA Establishment Labs
$78.96 /

-1.4 (-1.74%)

02/10/21 Cowen
Establishment Labs price target raised to $80 from $60 at Cowen
01/13/21 BTIG
Establishment Labs price target raised to $61 from $41 at BTIG
01/12/21 Jefferies
Allergan exits a 'clear win' for Establishment Labs, says Jefferies
08/27/20 UBS
Establishment Labs initiated with a Buy at UBS
ESTA Establishment Labs
$78.96 /

-1.4 (-1.74%)

Hot Stocks
Establishment Labs' Motiva implants study showed reduced foreign body response » 09:28
06/23/21
06/23
09:28
06/23/21
09:28
ESTA

Establishment Labs

$78.96 /

-1.4 (-1.74%)

Yesterday, Establishment…

Yesterday, Establishment Labs "announced results from a landmark study investigating how different breast implant surfaces affect the host immune response. The purpose of the study was to determine the optimal breast implant surface topography that induces the least amount of adverse foreign-body response and understand better how breast implant design impacts biocompatibility. The study... demonstrated that the patented Motiva(R) SmoothSilk surface* significantly reduces the foreign body response compared to implants with high degrees of roughness or completely smooth surfaces that were included in the study. The unique and patented SmoothSilk surface includes a number of elements purposefully designed to improve biocompatibility, including a topography of only 4 microns on average and specific characteristics around skewness and the number, distribution, and size of contact points. The study, led by a team of MIT researchers under the guidance of Professor Robert Langer and lead authors Joshua Doloff and Omid Veiseh, examined the foreign-body responses and capsular fibrosis triggered by miniaturized versions and human-scale commercially available breast implants with different surface topographies (including averages that varied from 0-90 microns) placed in the mammary fat pads of mice and rabbits, respectively, for up to one year. In both the mice and rabbit models, researchers found that tissue exposed to either implants with higher degrees of roughness or completely smooth implants showed increased levels of activity from macrophages - immune cells that normally clear out foreign cells and debris - as well as higher levels of activity in inflammatory T cells, and more scar tissue formation. Surfaces with the SmoothSilk architecture showed a significantly lower level of immune response and the most healthy and biocompatible tissue capsules compared to either completely smooth implants or those with rougher surfaces."

ShowHide Related Items >><<
ESTA Establishment Labs
$78.96 /

-1.4 (-1.74%)

ESTA Establishment Labs
$78.96 /

-1.4 (-1.74%)

02/10/21 Cowen
Establishment Labs price target raised to $80 from $60 at Cowen
01/13/21 BTIG
Establishment Labs price target raised to $61 from $41 at BTIG
01/12/21 Jefferies
Allergan exits a 'clear win' for Establishment Labs, says Jefferies
08/27/20 UBS
Establishment Labs initiated with a Buy at UBS
ESTA Establishment Labs
$78.96 /

-1.4 (-1.74%)

Over a month ago
Conference/Events
Establishment Labs management to meet virtually with BTIG » 04:55
05/14/21
05/14
04:55
05/14/21
04:55
ESTA

Establishment Labs

$65.53 /

-0.48 (-0.73%)

Virtual Meetings to be…

Virtual Meetings to be held on May 13-14 hosted by BTIG.

ShowHide Related Items >><<
ESTA Establishment Labs
$65.53 /

-0.48 (-0.73%)

ESTA Establishment Labs
$65.53 /

-0.48 (-0.73%)

02/10/21 Cowen
Establishment Labs price target raised to $80 from $60 at Cowen
01/13/21 BTIG
Establishment Labs price target raised to $61 from $41 at BTIG
01/12/21 Jefferies
Allergan exits a 'clear win' for Establishment Labs, says Jefferies
08/27/20 UBS
Establishment Labs initiated with a Buy at UBS
ESTA Establishment Labs
$65.53 /

-0.48 (-0.73%)

Conference/Events
Establishment Labs management to meet virtually with BTIG » 04:55
05/13/21
05/13
04:55
05/13/21
04:55
ESTA

Establishment Labs

$65.69 /

-1.93 (-2.85%)

Virtual Meetings to be…

Virtual Meetings to be held on May 13-14 hosted by BTIG.

ShowHide Related Items >><<
ESTA Establishment Labs
$65.69 /

-1.93 (-2.85%)

ESTA Establishment Labs
$65.69 /

-1.93 (-2.85%)

02/10/21 Cowen
Establishment Labs price target raised to $80 from $60 at Cowen
01/13/21 BTIG
Establishment Labs price target raised to $61 from $41 at BTIG
01/12/21 Jefferies
Allergan exits a 'clear win' for Establishment Labs, says Jefferies
08/27/20 UBS
Establishment Labs initiated with a Buy at UBS
ESTA Establishment Labs
$65.69 /

-1.93 (-2.85%)

Conference/Events
Establishment Labs management to meet virtually with BTIG » 12:06
05/07/21
05/07
12:06
05/07/21
12:06
ESTA

Establishment Labs

$72.46 /

+3.585 (+5.21%)

Virtual Meetings to be…

Virtual Meetings to be held on May 13-14 hosted by BTIG.

ShowHide Related Items >><<
ESTA Establishment Labs
$72.46 /

+3.585 (+5.21%)

ESTA Establishment Labs
$72.46 /

+3.585 (+5.21%)

02/10/21 Cowen
Establishment Labs price target raised to $80 from $60 at Cowen
01/13/21 BTIG
Establishment Labs price target raised to $61 from $41 at BTIG
01/12/21 Jefferies
Allergan exits a 'clear win' for Establishment Labs, says Jefferies
08/27/20 UBS
Establishment Labs initiated with a Buy at UBS
ESTA Establishment Labs
$72.46 /

+3.585 (+5.21%)

Earnings
Establishment Labs reports Q1 EPS (29c), consensus (34c) » 08:04
05/05/21
05/05
08:04
05/05/21
08:04
ESTA

Establishment Labs

$70.09 /

+0.955 (+1.38%)

Reports Q1 revenue…

Reports Q1 revenue $30.34M, consensus $25.3M. The company's cash balance on March 31, 2021 was $78M. Cash decreased $6.6M from December 31, 2020, primarily as the result of the operating loss in the quarter and changes in working capital. "We delivered record first quarter revenue of $30.3 million, which was up 24% from the first quarter of 2020 and 13% sequentially from the fourth quarter of 2020," said Juan Jose Chacon-Quiros, CEO. "With our strong first quarter results and continued momentum, we are raising full year 2021 revenue guidance to a new range of $118 million to $122 million, which is an annual growth rate of 39% to 44%."

ShowHide Related Items >><<
ESTA Establishment Labs
$70.09 /

+0.955 (+1.38%)

ESTA Establishment Labs
$70.09 /

+0.955 (+1.38%)

02/10/21 Cowen
Establishment Labs price target raised to $80 from $60 at Cowen
01/13/21 BTIG
Establishment Labs price target raised to $61 from $41 at BTIG
01/12/21 Jefferies
Allergan exits a 'clear win' for Establishment Labs, says Jefferies
08/27/20 UBS
Establishment Labs initiated with a Buy at UBS
ESTA Establishment Labs
$70.09 /

+0.955 (+1.38%)

Hot Stocks
Establishment Labs completes enrollment in Motiva Mia case series in Costa Rica » 08:05
04/27/21
04/27
08:05
04/27/21
08:05
ESTA

Establishment Labs

$74.20 /

+0.14 (+0.19%)

Establishment Labs…

Establishment Labs announced it has completed enrollment in its one hundred patient Motiva Mia case series in Costa Rica. The Institutional Review Board, or IRB, approved study began in December 2020 and follows the initial 2019 case series in Asia. Establishment Labs also announced that is has submitted the tools used in the Motiva Mia breast enhancement procedure for CE mark. Fifteen board-certified plastic surgeons from Costa Rica, Sweden, England, Brazil, Austria, Italy, Belgium, and the United States participated in the case series. The single-center study is a prospective, interventional, single-arm, feasibility study of women 18 years or older in primary minimally invasive breast enhancement.

ShowHide Related Items >><<
ESTA Establishment Labs
$74.20 /

+0.14 (+0.19%)

ESTA Establishment Labs
$74.20 /

+0.14 (+0.19%)

02/10/21 Cowen
Establishment Labs price target raised to $80 from $60 at Cowen
01/13/21 BTIG
Establishment Labs price target raised to $61 from $41 at BTIG
01/12/21 Jefferies
Allergan exits a 'clear win' for Establishment Labs, says Jefferies
08/27/20 UBS
Establishment Labs initiated with a Buy at UBS
ESTA Establishment Labs
$74.20 /

+0.14 (+0.19%)

Over a quarter ago
Earnings
Establishment Labs reports Q4 EPS ($1.63), consensus (19c) » 08:05
03/10/21
03/10
08:05
03/10/21
08:05
ESTA

Establishment Labs

$63.48 /

+3.63 (+6.07%)

Reports Q4 revenue $27M,…

Reports Q4 revenue $27M, consensus $25.27M."We delivered record fourth quarter revenue of $27.0 million, which was up 11% from the fourth quarter of 2019 and 18% from the third quarter of 2020," said Juan Jose Chacon-Quiros, Chief Executive Officer. "With a strong recovery from the pandemic well underway and with continued momentum in our business in the first quarter, we are issuing full year 2021 revenue guidance of $110 million to $112 million, which is an annual growth rate of 30% to 32%." "Our singular focus on women's health and the superior outcomes with our implants in the more than 80 countries in which we sell is resonating-and we continue to grow our total global market share." Mr. Chacon-Quiros continued. "As we look to 2021 and beyond, our regulatory and commercial timelines to begin selling Motiva implants in the U.S. and Chinese markets are progressing as planned. We have also made significant progress in advancing our portfolio of differentiated technologies and offerings, including Ergonomix2, Motiva Mia, and Flora, our novel tissue expander. We believe we are on track not only to become the leader in breast aesthetics and reconstruction, but to expand these markets as we offer safe, differentiated and accessible solutions to women."

ShowHide Related Items >><<
ESTA Establishment Labs
$63.48 /

+3.63 (+6.07%)

ESTA Establishment Labs
$63.48 /

+3.63 (+6.07%)

02/10/21 Cowen
Establishment Labs price target raised to $80 from $60 at Cowen
01/13/21 BTIG
Establishment Labs price target raised to $61 from $41 at BTIG
01/12/21 Jefferies
Allergan exits a 'clear win' for Establishment Labs, says Jefferies
08/27/20 UBS
Establishment Labs initiated with a Buy at UBS
ESTA Establishment Labs
$63.48 /

+3.63 (+6.07%)

ESTA Establishment Labs
$63.48 /

+3.63 (+6.07%)

Recommendations
Establishment Labs price target raised to $80 from $60 at Cowen » 08:29
02/10/21
02/10
08:29
02/10/21
08:29
ESTA

Establishment Labs

$65.10 /

+7.28 (+12.59%)

Cowen analyst Joshua…

Cowen analyst Joshua Jennings raised the firm's price target on Establishment Labs to $80 from $60 and keeps an Outperform rating on the shares. The analyst attended its investor event where management showcased its proprietary Motiva MIA surgery. He noted the promising minimally invasive platform triples its addressable market and believes investor sentiment will continue to improve.

ShowHide Related Items >><<
ESTA Establishment Labs
$65.10 /

+7.28 (+12.59%)

ESTA Establishment Labs
$65.10 /

+7.28 (+12.59%)

01/13/21 BTIG
Establishment Labs price target raised to $61 from $41 at BTIG
01/12/21 Jefferies
Allergan exits a 'clear win' for Establishment Labs, says Jefferies
08/27/20 UBS
Establishment Labs initiated with a Buy at UBS
05/14/20
Fly Intel: Top five analyst initiations
ESTA Establishment Labs
$65.10 /

+7.28 (+12.59%)

ESTA Establishment Labs
$65.10 /

+7.28 (+12.59%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.